System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish 1 citation

PubMed: 39591120 DOI: 10.3390/vaccines12111217

A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18-64 Years in the United States.

Vaccines (Basel) 12(11)

Authors: Myron J Levin, Neda Al Rawashdh, Liliane Mofor, Pablo Anaya, Richard M Zur, Emily B Kahn, Daniel Yu, Joaquin F Mould-Quevedo

Affiliations

  • Departments of Pediatrics and Medicine, Anschutz Medical Campus, University of Colorado, Aurora, CO 80045, USA.
  • Real-World Solutions, IQVIA, Falls Church, VA 22042, USA.
  • CSL Seqirus USA, Summit, NJ 07901, USA.
  • CSL Seqirus Australia, Melbourne 3052, Australia.

Abstract

BACKGROUND

This analysis compares the cost-effectiveness of a cell-based influenza vaccine to a recombinant influenza vaccine, and each to no vaccination. The analysis is based on United States (US) commercial and societal perspectives.

METHODS

A Susceptible-Exposed-Infectious-Recovered (SEIR) transmission model of the total US population followed with a cost-effectiveness model for 18-64-year-olds was used to estimate the clinical and economic impact of vaccination over one influenza season (2018-2019). Deterministic and probabilistic sensitivity analyses were conducted.

RESULTS

Both enhanced vaccines prevented a substantial number of influenza cases and influenza-related deaths compared to no vaccination. The cell-based vaccine was associated with higher quality-adjusted life years (QALYs) gained compared to the recombinant vaccine or no vaccination. The cell-based vaccine had a 36% lower vaccination cost, amounting to 2.8 billion in cost savings, compared to the recombinant vaccine. The incremental cost-effectiveness ratios (ICERs) for the cell-based vaccine, compared to the recombinant vaccine or no vaccination, were dominant from all payer perspectives, regardless of risk groups.

CONCLUSIONS

Overall, the cell-based vaccine was cost-saving compared to the recombinant vaccine for subjects aged 18-64 years in the US, achieving comparable health outcomes with a significant reduction in associated costs.

MeSH

Cells, Vaccines, Cost Savings, Vaccination, Influenza, Human, Influenza Vaccines, Quality-Adjusted Life Years